KCM
LGND icon

Kathmere Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Kathmere Capital Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-176
Closed -$11K – 290
2020
Q4 		$11K Hold
176
– – ﹤0.01% 315
2020
Q3 		$10K Buy
+176
New +$12K ﹤0.01% 301

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Kathmere Capital Management's LGND Position: Q1 2021 in Review

Kathmere Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q1 2021, closing a stake of 176 shares — an estimated $11K sold.

Kathmere Capital Management first reported a position in LGND in Q3 2020 and held it in 2 quarters. The position peaked at $11K in Q4 2020. 228 funds tracked by Wall St. Rank hold LGND as of Q1 2021.

  • Kathmere Capital Management reported no remaining Ligand Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Kathmere Capital Management sold 176 Ligand Pharmaceuticals shares in Q1 2021, an estimated $11K.
  • Kathmere Capital Management first reported a position in Ligand Pharmaceuticals in Q3 2020 and held it in 2 quarters.
  • Kathmere Capital Management's Ligand Pharmaceuticals position peaked at $11K in Q4 2020.
  • 228 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2021.

Based on Kathmere Capital Management's 13F filing for Q1 2021, filed 7 May 2021.